Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public titlesort icon Date of Registration State
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant 22/09/2022 Registered
NeuroEPO in mild-moderate Alzheimer's disease 20/09/2022 Registered
NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. 2010-12-29 Registered
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II 22/04/2016 Registered
Itolizumab-Plasmapheresis in patients with COVID-19 30/06/2021 Registered
Itolizumab Safety and Efficacy Study in Covid 19 26/03/2021 Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis 22/05/2015 Registered
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 08/10/2015 Registered
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus 23/12/2016 Registered
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders 18/06/2021 Registered outdated
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. 2010-12-29 Registered
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma. 2010-12-29 Registered
hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III. 2010-12-28 Registered
hR3 in metastatic or recurrent colorectal cancer 22/11/2013 Registered
Her1 vaccine in metastatic colon and prostate cancer 16/08/2023 Registered
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin. 2010-12-29 Registered
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. 2010-12-28 Registered
Evaluation of Safety and Efficacy of T1h (anti-CD6) as Monotherapy and in Combination with Methotrexate in Patientes with Rheumatoid Arthritis 2010-12-27 Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors 2013-06-19 Registered
EGF vaccine- Advanced Lung tumors 2013-06-20 Registered